StockData
City Therapeutics, Inc. logo

City Therapeutics, Inc. (CTY) company profile

CTYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.50+0.52 (+3.06%)

Close on Nov 17, 2026Market cap –P/E –Yield –

About City Therapeutics

Pharmaceutical Preparations, SIC 2834

City Therapeutics, Inc. is listed on Nasdaq under the ticker CTY, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31.

Company profile

Company

Legal name
City Therapeutics, Inc.
Headquarters
Cambridge, MA
Address
399 Binney St 02141
Phone
(857) 357-2024
Website
citytx.com
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
CTY
Exchange
Nasdaq
IPO date
Oct 16, 2026
Filer category
<br>Emerging growth company
SEC CIK
2143850
CUSIP
178782108
ISIN
US1787821081
FIGI
BBG01Q6VFNB7
Share class FIGI
BBG01Q6VFND5
EIN
93-2762122

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Andrew C. OrthPresident & CEO, Director1,063,154
Tracy ZimmermannChief Scientific Officer–
Keith RegnanteChief Financial Officer–
Baisong MeiChief Medical Officer228,743
Sebastian TrousilChief Operating Officer534,511
Barry E. GreeneDirector–
John MaraganoreDirector2,107,706
Sara NochurDirector–
Robert NelsenDirector13,692,507
Ron M. PhilipDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 16, 2026
Offer price
$18.00
Securities offered
11,111,111
Gross proceeds
$200.00M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 14, 2027

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?